Evogene (NASDAQ:EVGN) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Evogene (NASDAQ:EVGN) in a report released on Saturday. The brokerage issued a sell rating on the biotechnology company’s stock.

Evogene Trading Up 0.2 %

Shares of NASDAQ:EVGN opened at $1.42 on Friday. The company has a 50 day moving average of $1.58 and a 200 day moving average of $2.20. The stock has a market cap of $7.62 million, a P/E ratio of -0.32 and a beta of 1.29. Evogene has a 12 month low of $1.20 and a 12 month high of $10.40.

Hedge Funds Weigh In On Evogene

A hedge fund recently bought a new stake in Evogene stock. Citadel Advisors LLC bought a new stake in shares of Evogene Ltd. (NASDAQ:EVGN) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 15,891 shares of the biotechnology company’s stock, valued at approximately $30,000. Citadel Advisors LLC owned about 0.30% of Evogene at the end of the most recent reporting period. Institutional investors own 10.40% of the company’s stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.